http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 04:28:15 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Altimmune+%28ALT%29+Reiterated+at+Market+Outperform+By+Citizens+After+EASL+Presentation/26586168.html <p>Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $11.00 price target on Altimmune (NASDAQ: ALT).</p><p>The analyst commented, "We are pleased to see pemvidutide highlighted multiple times at EASL including a “Best of EASL 2026” designation for the first presentation of the 48-week Phase 2b IMPACT data for the hepatology meeting which was consistent with the company’s previous disclosures (our coverage here). Overall, the data should give investors more confidence in pemvidutide’s likelihood of hitting on fibrosis in Phase 3 with concordant NIT analyses showing clear separation from placebo and AI-based pathology reads showing a more pronounced treatment effect http://www.streetinsider.com/Analyst+Comments/Altimmune+%28ALT%29+Reiterated+at+Market+Outperform+By+Citizens+After+EASL+Presentation/26586168.html Tue, 02 Jun 2026 04:28:15 -0400 ALT http://www.streetinsider.com/FDA/Altimmune+reports+metabolic+improvements+for+MASH+drug+pemvidutide/26563463.html <p>Altimmune Inc. (NASDAQ: ALT) reported that its investigational drug pemvidutide demonstrated reductions in triglycerides and cholesterol levels in patients with metabolic dysfunction-associated steatohepatitis in 48-week trial data presented at the European Association for the Study of the Liver Congress 2026.</p> <p>The IMPACT Phase 2b trial showed pemvidutide 1.8 mg treatment resulted in triglyceride reductions of 23.7% and total cholesterol reductions of 15.4% among patients with elevated baseline values compared to placebo. The treatment also produced weight loss of 7.5%, reductions in body mass index of 3.0 kg/m2, and improvements in systolic blood pressure of 4.0 mmHg and diastolic blood pressure of http://www.streetinsider.com/FDA/Altimmune+reports+metabolic+improvements+for+MASH+drug+pemvidutide/26563463.html Thu, 28 May 2026 11:00:28 -0400 A.32868407 ALT O.00726404 O.22802303 http://www.streetinsider.com/FDA/Altimmune+reports+metabolic+improvements+for+MASH+drug+pemvidutide/26563463.html <p>Altimmune Inc. (NASDAQ: ALT) reported that its investigational drug pemvidutide demonstrated reductions in triglycerides and cholesterol levels in patients with metabolic dysfunction-associated steatohepatitis in 48-week trial data presented at the European Association for the Study of the Liver Congress 2026.</p> <p>The IMPACT Phase 2b trial showed pemvidutide 1.8 mg treatment resulted in triglyceride reductions of 23.7% and total cholesterol reductions of 15.4% among patients with elevated baseline values compared to placebo. The treatment also produced weight loss of 7.5%, reductions in body mass index of 3.0 kg/m2, and improvements in systolic blood pressure of 4.0 mmHg and diastolic blood pressure of http://www.streetinsider.com/FDA/Altimmune+reports+metabolic+improvements+for+MASH+drug+pemvidutide/26563463.html Thu, 28 May 2026 11:00:28 -0400 A.32868407 ALT O.00726404 O.22802303 http://www.streetinsider.com/FDA/Altimmune+reports+metabolic+improvements+for+MASH+drug+pemvidutide/26563463.html <p>Altimmune Inc. (NASDAQ: ALT) reported that its investigational drug pemvidutide demonstrated reductions in triglycerides and cholesterol levels in patients with metabolic dysfunction-associated steatohepatitis in 48-week trial data presented at the European Association for the Study of the Liver Congress 2026.</p> <p>The IMPACT Phase 2b trial showed pemvidutide 1.8 mg treatment resulted in triglyceride reductions of 23.7% and total cholesterol reductions of 15.4% among patients with elevated baseline values compared to placebo. The treatment also produced weight loss of 7.5%, reductions in body mass index of 3.0 kg/m2, and improvements in systolic blood pressure of 4.0 mmHg and diastolic blood pressure of http://www.streetinsider.com/FDA/Altimmune+reports+metabolic+improvements+for+MASH+drug+pemvidutide/26563463.html Thu, 28 May 2026 11:00:28 -0400 A.32868407 ALT O.00726404 O.22802303 http://www.streetinsider.com/FDA/Altimmune+reports+metabolic+improvements+for+MASH+drug+pemvidutide/26563463.html <p>Altimmune Inc. (NASDAQ: ALT) reported that its investigational drug pemvidutide demonstrated reductions in triglycerides and cholesterol levels in patients with metabolic dysfunction-associated steatohepatitis in 48-week trial data presented at the European Association for the Study of the Liver Congress 2026.</p> <p>The IMPACT Phase 2b trial showed pemvidutide 1.8 mg treatment resulted in triglyceride reductions of 23.7% and total cholesterol reductions of 15.4% among patients with elevated baseline values compared to placebo. The treatment also produced weight loss of 7.5%, reductions in body mass index of 3.0 kg/m2, and improvements in systolic blood pressure of 4.0 mmHg and diastolic blood pressure of http://www.streetinsider.com/FDA/Altimmune+reports+metabolic+improvements+for+MASH+drug+pemvidutide/26563463.html Thu, 28 May 2026 11:00:28 -0400 A.32868407 ALT O.00726404 O.22802303 http://www.streetinsider.com/Press+Releases/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html <p align="center"><em>“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors</em></p> <p align="center"><em>PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide</em></p> <p>GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Rmb7JOcEo9rXwIQdT1ikOSwVa7SNyauleg8kHP4sRVxoAd9la1cK1ZU3mIm32g0JEyggQD6rhvMJx7MXNeYmOg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple http://www.streetinsider.com/Press+Releases/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html Thu, 28 May 2026 11:00:00 -0400 A.32868407 ALT O.00726404 O.22802303 http://www.streetinsider.com/Press+Releases/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html <p align="center"><em>“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors</em></p> <p align="center"><em>PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide</em></p> <p>GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Rmb7JOcEo9rXwIQdT1ikOSwVa7SNyauleg8kHP4sRVxoAd9la1cK1ZU3mIm32g0JEyggQD6rhvMJx7MXNeYmOg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple http://www.streetinsider.com/Press+Releases/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html Thu, 28 May 2026 11:00:00 -0400 A.32868407 ALT O.00726404 O.22802303 http://www.streetinsider.com/Press+Releases/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html <p align="center"><em>“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors</em></p> <p align="center"><em>PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide</em></p> <p>GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Rmb7JOcEo9rXwIQdT1ikOSwVa7SNyauleg8kHP4sRVxoAd9la1cK1ZU3mIm32g0JEyggQD6rhvMJx7MXNeYmOg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple http://www.streetinsider.com/Press+Releases/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html Thu, 28 May 2026 11:00:00 -0400 A.32868407 ALT O.00726404 O.22802303 http://www.streetinsider.com/Press+Releases/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html <p align="center"><em>“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors</em></p> <p align="center"><em>PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide</em></p> <p>GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Rmb7JOcEo9rXwIQdT1ikOSwVa7SNyauleg8kHP4sRVxoAd9la1cK1ZU3mIm32g0JEyggQD6rhvMJx7MXNeYmOg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple http://www.streetinsider.com/Press+Releases/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html Thu, 28 May 2026 11:00:00 -0400 A.32868407 ALT O.00726404 O.22802303 http://www.streetinsider.com/Globe+Newswire/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html <p align="center"><em>“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors</em></p> <p align="center"><em>PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide</em></p> <p>GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Rmb7JOcEo9rXwIQdT1ikOSwVa7SNyauleg8kHP4sRVxoAd9la1cK1ZU3mIm32g0JEyggQD6rhvMJx7MXNeYmOg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple http://www.streetinsider.com/Globe+Newswire/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html Thu, 28 May 2026 11:00:00 -0400 A.32868407 ALT O.00726404 O.22802303 http://www.streetinsider.com/Globe+Newswire/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html <p align="center"><em>“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors</em></p> <p align="center"><em>PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide</em></p> <p>GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Rmb7JOcEo9rXwIQdT1ikOSwVa7SNyauleg8kHP4sRVxoAd9la1cK1ZU3mIm32g0JEyggQD6rhvMJx7MXNeYmOg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple http://www.streetinsider.com/Globe+Newswire/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html Thu, 28 May 2026 11:00:00 -0400 A.32868407 ALT O.00726404 O.22802303 http://www.streetinsider.com/Globe+Newswire/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html <p align="center"><em>“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors</em></p> <p align="center"><em>PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide</em></p> <p>GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Rmb7JOcEo9rXwIQdT1ikOSwVa7SNyauleg8kHP4sRVxoAd9la1cK1ZU3mIm32g0JEyggQD6rhvMJx7MXNeYmOg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple http://www.streetinsider.com/Globe+Newswire/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html Thu, 28 May 2026 11:00:00 -0400 A.32868407 ALT O.00726404 O.22802303 http://www.streetinsider.com/Globe+Newswire/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html <p align="center"><em>“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors</em></p> <p align="center"><em>PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide</em></p> <p>GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Rmb7JOcEo9rXwIQdT1ikOSwVa7SNyauleg8kHP4sRVxoAd9la1cK1ZU3mIm32g0JEyggQD6rhvMJx7MXNeYmOg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple http://www.streetinsider.com/Globe+Newswire/Pemvidutide+Demonstrates+Significant+Metabolic+Improvements+in+Patients+with+MASH+in+New+48%E2%80%91Week+IMPACT+Phase+2b+Data+Presented+at+EASL+2026/26563446.html Thu, 28 May 2026 11:00:00 -0400 A.32868407 ALT O.00726404 O.22802303 http://www.streetinsider.com/Press+Releases/Altimmune+to+Participate+in+Upcoming+Investor+Conferences/26554077.html <p align="left">GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7-Z5xYGuWSfHFnGLTQMosLYNgxTWEJnIKNQ7y_QRFo_Sb09TL1vTKRFQf5m14W-gT0suNqGim4SVHrq0O0tFhg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:</p> <ul type="disc"><li><strong>2026 Jefferies Global Healthcare Conference<br/></strong>Thursday, June 4, 2026<br/>Fireside chat at 12:50 p.m. ET<br/>New York, NY<br/></li></ul> <ul type="disc"><li><strong>Goldman Sachs 47</strong><strong>th</strong><strong> Annual Global Healthcare Conference </strong><br/>Wednesday, June 10, 2026<br/>Fireside chat at 8:00 a.m. ET<br/>Miami Beach, FL<br/></li></ul> <p>A webcast of the fireside chats will be available via the <a target="_blank" http://www.streetinsider.com/Press+Releases/Altimmune+to+Participate+in+Upcoming+Investor+Conferences/26554077.html Wed, 27 May 2026 08:30:00 -0400 ALT O.00726404 http://www.streetinsider.com/Press+Releases/Altimmune+to+Participate+in+Upcoming+Investor+Conferences/26554077.html <p align="left">GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7-Z5xYGuWSfHFnGLTQMosLYNgxTWEJnIKNQ7y_QRFo_Sb09TL1vTKRFQf5m14W-gT0suNqGim4SVHrq0O0tFhg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:</p> <ul type="disc"><li><strong>2026 Jefferies Global Healthcare Conference<br/></strong>Thursday, June 4, 2026<br/>Fireside chat at 12:50 p.m. ET<br/>New York, NY<br/></li></ul> <ul type="disc"><li><strong>Goldman Sachs 47</strong><strong>th</strong><strong> Annual Global Healthcare Conference </strong><br/>Wednesday, June 10, 2026<br/>Fireside chat at 8:00 a.m. ET<br/>Miami Beach, FL<br/></li></ul> <p>A webcast of the fireside chats will be available via the <a target="_blank" http://www.streetinsider.com/Press+Releases/Altimmune+to+Participate+in+Upcoming+Investor+Conferences/26554077.html Wed, 27 May 2026 08:30:00 -0400 ALT O.00726404 http://www.streetinsider.com/Globe+Newswire/Altimmune+to+Participate+in+Upcoming+Investor+Conferences/26554077.html <p align="left">GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7-Z5xYGuWSfHFnGLTQMosLYNgxTWEJnIKNQ7y_QRFo_Sb09TL1vTKRFQf5m14W-gT0suNqGim4SVHrq0O0tFhg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:</p> <ul type="disc"><li><strong>2026 Jefferies Global Healthcare Conference<br/></strong>Thursday, June 4, 2026<br/>Fireside chat at 12:50 p.m. ET<br/>New York, NY<br/></li></ul> <ul type="disc"><li><strong>Goldman Sachs 47</strong><strong>th</strong><strong> Annual Global Healthcare Conference </strong><br/>Wednesday, June 10, 2026<br/>Fireside chat at 8:00 a.m. ET<br/>Miami Beach, FL<br/></li></ul> <p>A webcast of the fireside chats will be available via the <a target="_blank" http://www.streetinsider.com/Globe+Newswire/Altimmune+to+Participate+in+Upcoming+Investor+Conferences/26554077.html Wed, 27 May 2026 08:30:00 -0400 ALT O.00726404 http://www.streetinsider.com/Globe+Newswire/Altimmune+to+Participate+in+Upcoming+Investor+Conferences/26554077.html <p align="left">GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7-Z5xYGuWSfHFnGLTQMosLYNgxTWEJnIKNQ7y_QRFo_Sb09TL1vTKRFQf5m14W-gT0suNqGim4SVHrq0O0tFhg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:</p> <ul type="disc"><li><strong>2026 Jefferies Global Healthcare Conference<br/></strong>Thursday, June 4, 2026<br/>Fireside chat at 12:50 p.m. ET<br/>New York, NY<br/></li></ul> <ul type="disc"><li><strong>Goldman Sachs 47</strong><strong>th</strong><strong> Annual Global Healthcare Conference </strong><br/>Wednesday, June 10, 2026<br/>Fireside chat at 8:00 a.m. ET<br/>Miami Beach, FL<br/></li></ul> <p>A webcast of the fireside chats will be available via the <a target="_blank" http://www.streetinsider.com/Globe+Newswire/Altimmune+to+Participate+in+Upcoming+Investor+Conferences/26554077.html Wed, 27 May 2026 08:30:00 -0400 ALT O.00726404 http://www.streetinsider.com/FDA/Altimmune+presents+phase+2b+trial+data+showing+pemvidutide+liver+benefits/26553830.html <p>Altimmune Inc. (NASDAQ: ALT) presented data from its IMPACT Phase 2b trial at the European Association for the Study of the Liver Congress 2026, showing that pemvidutide demonstrated improvements across multiple non-invasive markers of metabolic dysfunction-associated steatohepatitis at 24 weeks.</p> <p>The trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2 or F3. Participants received weekly subcutaneous doses of pemvidutide at 1.2 mg, 1.8 mg, or placebo for 48 weeks in a randomized, double-blind study.</p> <p>Results showed that 37.8% of patients taking pemvidutide 1.2 mg and 22.7% taking 1.8 mg achieved concurrent enhanced liver fibrosis reduction plus liver stiffness measurement reduction http://www.streetinsider.com/FDA/Altimmune+presents+phase+2b+trial+data+showing+pemvidutide+liver+benefits/26553830.html Wed, 27 May 2026 08:01:10 -0400 ALT O.00726404 http://www.streetinsider.com/FDA/Altimmune+presents+phase+2b+trial+data+showing+pemvidutide+liver+benefits/26553830.html <p>Altimmune Inc. (NASDAQ: ALT) presented data from its IMPACT Phase 2b trial at the European Association for the Study of the Liver Congress 2026, showing that pemvidutide demonstrated improvements across multiple non-invasive markers of metabolic dysfunction-associated steatohepatitis at 24 weeks.</p> <p>The trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2 or F3. Participants received weekly subcutaneous doses of pemvidutide at 1.2 mg, 1.8 mg, or placebo for 48 weeks in a randomized, double-blind study.</p> <p>Results showed that 37.8% of patients taking pemvidutide 1.2 mg and 22.7% taking 1.8 mg achieved concurrent enhanced liver fibrosis reduction plus liver stiffness measurement reduction http://www.streetinsider.com/FDA/Altimmune+presents+phase+2b+trial+data+showing+pemvidutide+liver+benefits/26553830.html Wed, 27 May 2026 08:01:10 -0400 ALT O.00726404 http://www.streetinsider.com/Press+Releases/New+IMPACT+Phase+2b+Data+Highlight+Concurrent+Improvements+Across+Multiple+Non-Invasive+Markers+and+qFibrosis-Measured+Fibrosis+Regression+with+Pemvidutide+in+MASH+at+EASL+2026/26553818.html <p align="center"><em>Concurrent improvement across key non-invasive tests underscores convergence of </em><br/><em>pemvidutide effects on MASH disease activity and fibrosis</em></p> <p align="center"><em> AI-based digital pathology analyses further demonstrate antifibrotic effects of pemvidutide </em><br/><em>at 24 weeks</em></p> <p>GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MgWaTxUdQZTk0WCLqrIj4T_i6jo0J8ucY_h2XZGwrCnny7xA_7_2e8cp4wtEL_mdSIvl3XP8GsNsevO-Orzmeg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new analyses of data from the IMPACT Phase 2b trial demonstrated that treatment with pemvidutide, an investigational, balanced 1:1 glucagon/GLP-1 dual receptor agonist, is associated with concurrent improvements across multiple non-invasive tests (NITs) http://www.streetinsider.com/Press+Releases/New+IMPACT+Phase+2b+Data+Highlight+Concurrent+Improvements+Across+Multiple+Non-Invasive+Markers+and+qFibrosis-Measured+Fibrosis+Regression+with+Pemvidutide+in+MASH+at+EASL+2026/26553818.html Wed, 27 May 2026 08:00:00 -0400 ALT O.00726404 http://www.streetinsider.com/Press+Releases/New+IMPACT+Phase+2b+Data+Highlight+Concurrent+Improvements+Across+Multiple+Non-Invasive+Markers+and+qFibrosis-Measured+Fibrosis+Regression+with+Pemvidutide+in+MASH+at+EASL+2026/26553818.html <p align="center"><em>Concurrent improvement across key non-invasive tests underscores convergence of </em><br/><em>pemvidutide effects on MASH disease activity and fibrosis</em></p> <p align="center"><em> AI-based digital pathology analyses further demonstrate antifibrotic effects of pemvidutide </em><br/><em>at 24 weeks</em></p> <p>GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MgWaTxUdQZTk0WCLqrIj4T_i6jo0J8ucY_h2XZGwrCnny7xA_7_2e8cp4wtEL_mdSIvl3XP8GsNsevO-Orzmeg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new analyses of data from the IMPACT Phase 2b trial demonstrated that treatment with pemvidutide, an investigational, balanced 1:1 glucagon/GLP-1 dual receptor agonist, is associated with concurrent improvements across multiple non-invasive tests (NITs) http://www.streetinsider.com/Press+Releases/New+IMPACT+Phase+2b+Data+Highlight+Concurrent+Improvements+Across+Multiple+Non-Invasive+Markers+and+qFibrosis-Measured+Fibrosis+Regression+with+Pemvidutide+in+MASH+at+EASL+2026/26553818.html Wed, 27 May 2026 08:00:00 -0400 ALT O.00726404 http://www.streetinsider.com/Globe+Newswire/New+IMPACT+Phase+2b+Data+Highlight+Concurrent+Improvements+Across+Multiple+Non-Invasive+Markers+and+qFibrosis-Measured+Fibrosis+Regression+with+Pemvidutide+in+MASH+at+EASL+2026/26553818.html <p align="center"><em>Concurrent improvement across key non-invasive tests underscores convergence of </em><br/><em>pemvidutide effects on MASH disease activity and fibrosis</em></p> <p align="center"><em> AI-based digital pathology analyses further demonstrate antifibrotic effects of pemvidutide </em><br/><em>at 24 weeks</em></p> <p>GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MgWaTxUdQZTk0WCLqrIj4T_i6jo0J8ucY_h2XZGwrCnny7xA_7_2e8cp4wtEL_mdSIvl3XP8GsNsevO-Orzmeg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new analyses of data from the IMPACT Phase 2b trial demonstrated that treatment with pemvidutide, an investigational, balanced 1:1 glucagon/GLP-1 dual receptor agonist, is associated with concurrent improvements across multiple non-invasive tests (NITs) http://www.streetinsider.com/Globe+Newswire/New+IMPACT+Phase+2b+Data+Highlight+Concurrent+Improvements+Across+Multiple+Non-Invasive+Markers+and+qFibrosis-Measured+Fibrosis+Regression+with+Pemvidutide+in+MASH+at+EASL+2026/26553818.html Wed, 27 May 2026 08:00:00 -0400 ALT O.00726404 http://www.streetinsider.com/Globe+Newswire/New+IMPACT+Phase+2b+Data+Highlight+Concurrent+Improvements+Across+Multiple+Non-Invasive+Markers+and+qFibrosis-Measured+Fibrosis+Regression+with+Pemvidutide+in+MASH+at+EASL+2026/26553818.html <p align="center"><em>Concurrent improvement across key non-invasive tests underscores convergence of </em><br/><em>pemvidutide effects on MASH disease activity and fibrosis</em></p> <p align="center"><em> AI-based digital pathology analyses further demonstrate antifibrotic effects of pemvidutide </em><br/><em>at 24 weeks</em></p> <p>GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MgWaTxUdQZTk0WCLqrIj4T_i6jo0J8ucY_h2XZGwrCnny7xA_7_2e8cp4wtEL_mdSIvl3XP8GsNsevO-Orzmeg==" rel="nofollow" target="_blank">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new analyses of data from the IMPACT Phase 2b trial demonstrated that treatment with pemvidutide, an investigational, balanced 1:1 glucagon/GLP-1 dual receptor agonist, is associated with concurrent improvements across multiple non-invasive tests (NITs) http://www.streetinsider.com/Globe+Newswire/New+IMPACT+Phase+2b+Data+Highlight+Concurrent+Improvements+Across+Multiple+Non-Invasive+Markers+and+qFibrosis-Measured+Fibrosis+Regression+with+Pemvidutide+in+MASH+at+EASL+2026/26553818.html Wed, 27 May 2026 08:00:00 -0400 ALT O.00726404 http://www.streetinsider.com/Analyst+PT+Change/Altimmune+%28ALT%29+PT+Lowered+to+%2420+at+H.C.+Wainwright/26516904.html (Updated - May 19, 2026 6:48 AM EDT) <p>H.C. Wainwright analyst Patrick Trucchio lowered the price target on Altimmune (NASDAQ: ALT) to $20.00 (from $25.00) while maintaining a Buy rating.</p><p>The analyst commented: "On May 13, Altimmune reported 1Q26 results and a business update highlighted by three key incremental positives: (1) the global Phase 3 trial (PERFORMA) in metabolic dysfunction-associated steatohepatitis (MASH) has been finalized, submitted to the FDA, and aligned with EMA feedback, with screening on track to begin in 2H26; (2) alcohol-related disease catalysts are approaching, with topline data from the Phase 2 trial (RECLAIM) in alcohol use disorder (AUD) http://www.streetinsider.com/Analyst+PT+Change/Altimmune+%28ALT%29+PT+Lowered+to+%2420+at+H.C.+Wainwright/26516904.html Tue, 19 May 2026 06:48:35 -0400 ALT http://www.streetinsider.com/Analyst+Comments/Altimmune+%28ALT%29+PT+Lowered+to+%2420+at+H.C.+Wainwright/26516904.html (Updated - May 19, 2026 6:48 AM EDT) <p>H.C. Wainwright analyst Patrick Trucchio lowered the price target on Altimmune (NASDAQ: ALT) to $20.00 (from $25.00) while maintaining a Buy rating.</p><p>The analyst commented: "On May 13, Altimmune reported 1Q26 results and a business update highlighted by three key incremental positives: (1) the global Phase 3 trial (PERFORMA) in metabolic dysfunction-associated steatohepatitis (MASH) has been finalized, submitted to the FDA, and aligned with EMA feedback, with screening on track to begin in 2H26; (2) alcohol-related disease catalysts are approaching, with topline data from the Phase 2 trial (RECLAIM) in alcohol use disorder (AUD) http://www.streetinsider.com/Analyst+Comments/Altimmune+%28ALT%29+PT+Lowered+to+%2420+at+H.C.+Wainwright/26516904.html Tue, 19 May 2026 06:48:35 -0400 ALT